Nan Fung Group Holdings Ltd
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 13, 2025), Nan Fung Group Holdings Ltd reported 24 stock positions worth $59.6 million. Its top holding was Oculis (OCS) at 15.2% of the portfolio, followed by Madrigal Pharmaceuticals (MDGL, 9.1%) and Beone Medicines Ltd.-ADR (ONC, 9.0%). Compared with Q2 2025, it opened 5 new positions, sold out of 1 and reduced 2. The biggest buy was a new position in LB Pharmaceuticals (LBRX) and the biggest sale an exit from Illumina (ILMN).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $59.6M (Q3 2025)
- SEC Filing
- 0001012975-25-000750 ↗ filed Nov 13, 2025
Holdings Value
Holdings 24 stocks · $59.6M
| OCS Oculis Holding AG | 15.18% | 514,702 | $9.0M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 9.13% | 11,872 | $5.4M | No change |
| ONC Beone Medicines Ltd.-ADR | 8.99% | 15,722 | $5.4M | No change |
| INCY Incyte Corp. | 8.40% | 59,022 | $5.0M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 8.32% | 49,120 | $5.0M | No change |
| LBRX LB Pharmaceuticals Inc. | 7.95% | 300,000 | $4.7M | New |
| JOBY Joby Aviation Inc. | 5.88% | 217,320 | $3.5M | New |
| RXRX Recursion Pharmaceuticals-A | 4.87% | 595,287 | $2.9M | Reduce -10.4% |
| ASND Ascendis Pharma A/S | 4.54% | 13,600 | $2.7M | No change |
| LAB Standard Biotools Inc. | 4.11% | 1,883,179 | $2.4M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 3.69% | 102,984 | $2.2M | No change |
| ARGX Argenx SE - ADR | 3.46% | 2,800 | $2.1M | No change |
| KYMR Kymera Therapeutics Inc. | 2.93% | 30,875 | $1.7M | No change |
| ETHA iShares Ethereum Trust ETF | 2.67% | 50,549 | $1.6M | New |
| RKLB Rocket Lab Corp. | 2.37% | 29,540 | $1.4M | New |
| IBIT iShares Bitcoin Trust ETF | 1.74% | 15,968 | $1.0M | New |
| RVMD Revolution Medicines Inc. | 1.51% | 19,253 | $899K | No change |
| HRMY Harmony Biosciences Holdings | 1.25% | 27,049 | $745K | Reduce -92.7% |
| BCYC Bicycle Therapeutics PLC-ADR | 0.90% | 68,943 | $534K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.52% | 58,347 | $310K | No change |
| TRDA Entrada Therapeutics Inc. | 0.48% | 49,082 | $285K | No change |
| REPL Replimune Group Inc. | 0.45% | 63,719 | $267K | No change |
| RANI Rani Therapeutics Holdings Class A | 0.41% | 493,584 | $247K | No change |
| BSLK Bolt Projects Holdings Inc. | 0.26% | 40,597 | $153K | No change |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |